乳腺癌

乳腺癌是一種起源于乳腺上皮細胞的惡性腫瘤，是女性中最常見的癌癥之一，也是導致女性癌癥死亡的主要原因之一。乳腺癌的發病率與多種因素有關，包括遺傳、年齡、激素水平、生活方式等。根據腫瘤細胞的特征，乳腺癌可以分為不同的亞型，如激素受體陽性（ER+/PR+）、人表皮生長因子受體2（HER2+）和三陰性乳腺癌（TNBC）等。

近年來，乳腺癌的治療和藥物研發取得了顯著進展。特別是在靶向治療和免疫治療領域，新藥物和新療法的不斷涌現為患者帶來了更多的治療選擇和更好的預后。

靶向治療藥物

● HER2陽性乳腺癌

HER2陽性乳腺癌的治療在過去幾年中取得了重大進展。ADC（抗體藥物偶聯物）類藥物治療是HER2陽性乳腺癌治療的重要突破。例如，DS-8201（Trastuzumab Deruxtecan）是一種針對HER2的ADC藥物，已經在臨床試驗中顯示出對HER2低表達和HER2陰性乳腺癌患者的潛在療效67。此外，T-DM1（Trastuzumab Emtansine）和T-DXd（Trastuzumab Deruxtecan）也在HER2陽性乳腺癌的治療中取得了成功。

● 激素受體陽性乳腺癌

對于激素受體陽性的乳腺癌，CDK4/6抑制劑如阿貝西利（Abemaciclib）、達爾西利（Dalpiciclib）和瑞波西利（Ribociclib）等藥物的開發為患者提供了新的治療選擇。這些藥物通過抑制細胞周期的關鍵調節因子，減緩腫瘤細胞的生長和擴散。

● 三陰性乳腺癌

三陰性乳腺癌（TNBC）是一種較為難治的亞型，因為它缺乏激素受體和HER2的表達。然而，免疫治療在這一領域取得了進展，例如PD-1/PD-L1抑制劑在TNBC的治療中顯示出潛力。

免疫治療藥物

免疫治療是乳腺癌治療領域的另一個重要進展。免疫檢查點抑制劑，如PD-1和PD-L1抑制劑，已經在三陰性乳腺癌的治療中顯示出一定的療效。此外，研究者正在探索將免疫治療與其他治療方法結合使用的策略，以提高治療效果。

乳腺癌藥物靶點

乳腺癌藥物靶點相關產品推薦

● 靶點蛋白

ERBB2
CSB-MP007763HU

Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC₅₀ is 2.179-2.825 ng/ml.

PDCD1
CSB-MP619964HU1

Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC₅₀ of human PD-1 protein is 6.087-7.854 ng/ml.

CD274
CSB-MP878942HU1

Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody (CSB-MA878942A1m, antigen from E.coli), the EC₅₀ of human PD-L1 protein is 1.252-1.653 ng/mL

TACSTD2
CSB-MP023072HU1

Measured in cell activity assay using U937 cells, the EC₅₀ for this effect is 190.2-298.6 ng/ml.

ERBB3
CSB-MP007765HU

Measured by its binding ability in a functional ELISA. Immobilized NRG1 (CSB-MP016077HU1(F6)) at 2 μg/ml can bind human ERBB3, the EC₅₀ is 12.32-15.74 ng/ml.

CTLA4
CSB-MP006163HU1

Measured by its binding ability in a functional ELISA. Immobilized CD152 at 2 μg/ml can bind Anti-CD152 rabbit monoclonal antibody (CSB-RA213310A0HU), the EC₅₀ of human CD152 protein is 27.14-34.82 ng/ml.

CD47
CSB-MP004940HU

Human SIRPA protein His/Myc tag (CSB-MP021334HU) captured on COOH chip can bind Human CD47 protein Fc tag (CSB-MP004940HU) with an affinity constant of 19.1 nM as detected by LSPR Assay.

EGFR
CSB-MP007479HU

Human EGF protein captured on COOH chip can bind Human EGFR protein, his and Myc tag (CSB-MP007479HU) with an affinity constant of 11.9nM as detected by LSPR Assay.

產品名稱	貨號	靶點	來源	蛋白標簽
Recombinant Human Programmed cell death 1 ligand 1 (CD274), partial (Active)	CSB-MP878942HU1	CD274	Mammalian cell	C-terminal hFc-tagged
Recombinant Human CD276 antigen (CD276), partial (Active)	CSB-MP733578HU	CD276	Mammalian cell	C-terminal hFc-Myc-tagged
Recombinant Human Tumor necrosis factor receptor superfamily member 5 (CD40), partial (Active)	CSB-MP004936HU1	CD40	Mammalian cell	C-terminal hFc-tagged
Recombinant Macaca fascicularis CD44 antigen (CD44), partial (Active)	CSB-MP4290MOV	CD44	Mammalian cell	C-terminal 10xHis-tagged
Recombinant Human CD44 antigen (CD44), partial, Biotinylated (Active)	CSB-MP004938HU(F1)j1-B	CD44	Mammalian cell	C-terminal mFc-Avi-tagged
Recombinant Human CD44 antigen (CD44), partial (Active)	CSB-MP004938HU(F1)	CD44	Mammalian cell	C-terminal hFc-tagged
Recombinant Human Leukocyte surface antigen CD47 (CD47), partial (Active)	CSB-MP004940HU	CD47	Mammalian cell	C-terminal hFc-tagged
Recombinant Human Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) (E398K) (Active)	CSB-MP005165HU	CEACAM5	Mammalian cell	C-terminal?10xHis-tagged
Recombinant Human Cytotoxic T-lymphocyte protein 4 (CTLA4), partial (Active)	CSB-MP006163HU1	CTLA4	Mammalian cell	C-terminal hFc-tagged
Recombinant Human Epidermal growth factor receptor (EGFR), partial (Active)	CSB-MP007479HU	EGFR	Mammalian cell	N-terminal 10xHis-tagged and C-terminal Myc-tagged
Recombinant Human Receptor tyrosine-protein kinase erbB-2 (ERBB2), partial (Active)	CSB-MP007763HU	ERBB2	Mammalian cell	C-terminal 6xHis-tagged
Recombinant Human Receptor tyrosine-protein kinase erbB-3 (ERBB3), partial (Active)	CSB-MP007765HU	ERBB3	Mammalian cell	C-terminal hFc-tagged
Recombinant Human Interleukin-2 (IL2) (Active)	CSB-MP011629HU	IL2	Mammalian cell	N-terminal hFc-tagged
Recombinant Human Interleukin-2 receptor subunit alpha (IL2RA), partial (Active)	CSB-MP011649HU3	IL2RA	Mammalian cell	C-terminal 10xHis-tagged
Recombinant Human Hepatocyte growth factor receptor (MET), partial (Active)	CSB-MP013714HU	MET	Mammalian cell	C-terminal hFc-tagged
Recombinant Human Mesothelin (MSLN), partial (Active)	CSB-MP015044HUc9	MSLN	Mammalian cell	N-terminal hFc-tagged
Recombinant Human Mucin-16 (MUC16), partial (Active)	CSB-MP704410HU3c7	MUC16	Mammalian cell	C-terminal 6xHis-tagged
Recombinant Human Nectin-4 (NECTIN4), partial (Active)	CSB-MP822274HU	NECTIN4	Mammalian cell	C-terminal 10xHis-tagged
Recombinant Human 5'-nucleotidase (NT5E) (Active)	CSB-MP723415HU	NT5E	Mammalian cell	C-terminal 6xHis-tagged
Recombinant Human Programmed cell death protein 1 (PDCD1), partial (Active)	CSB-MP619964HU1	PDCD1	Mammalian cell	C-terminal 6xHis-tagged

● 穩定細胞株

CT26/Human ROR1 Stable Cell Line

CSB-SC020067HU

Untransfected CT26 cells (green line) and transfected Human ROR1 CT26 stable cells (red line) were stained with anti-ROR1 antibody (CSB-RA020067A1HU) (2μg/1*10⁶ cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.

● 重組抗體

ERBB2 Recombinant Monoclonal Antibody
CSB-RA260392A0HU

IHC image of CSB-RA260392A0HU diluted at 1:100 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system.

MET Recombinant Monoclonal Antibody
CSB-RA634199A0HU

IHC image of CSB-RA634199A0HU diluted at 1:100 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system.

CD44 Recombinant Monoclonal Antibody
CSB-RA292372A0HU

Overlay Peak curve showing Hela cells surface stained with CSB-RA292372A0HU (red line) at 1:50.

EGFR Recombinant Monoclonal Antibody
CSB-RA159341A0HU

Overlay histogram showing Jurkat cells stained with CSB-RA159341A0HU (red line) at 1:50.

產品名稱	貨號	靶點	反應種屬	應用范圍
CA9 Recombinant Monoclonal Antibody	CSB-RA614990A0HU	CA9	Human	ELISA, IHC
CD247 Recombinant Monoclonal Antibody	CSB-RA244537A0HU	CD247	Human	ELISA, FC
CD27 Recombinant Monoclonal Antibody	CSB-RA953976A0HU	CD27	Human	ELISA, WB
CD274 Recombinant Monoclonal Antibody	CSB-RA977797A0HU	CD274	Human	ELISA, WB, IHC
CD274 Recombinant Monoclonal Antibody	CSB-RA878942MA1HU	CD274	Human	ELISA, IHC, FC
CD40 Recombinant Monoclonal Antibody	CSB-RA004936MA1HU	CD40	Human	ELISA, IF, FC
CD44 Recombinant Monoclonal Antibody	CSB-RA004938A0HU	CD44	Human	ELISA, WB, IHC
CD44 Recombinant Monoclonal Antibody	CSB-RA292372A0HU	CD44	Human	ELISA, WB, IHC, IF, FC
CD44 Recombinant Monoclonal Antibody	CSB-RA004938MA1HU	CD44	Human	ELISA, FC
CD47 Recombinant Monoclonal Antibody	CSB-RA802124A0HU	CD47	Human	ELISA, WB, IHC, IF
CEACAM5 Recombinant Monoclonal Antibody	CSB-RA005165MA3HU	CEACAM5	Human	ELISA, IF, FC
CEACAM5 Recombinant Monoclonal Antibody	CSB-RA005165MA1HU	CEACAM5	Human	ELISA
CTLA4 Recombinant Monoclonal Antibody	CSB-RA213310A0HU	CTLA4	Human	ELISA, IHC
CTLA4 Recombinant Monoclonal Antibody	CSB-RA006163MA1HU	CTLA4	Human, Mouse	ELISA, WB, IF, FC
Phospho-EGFR (Y1092) Recombinant Monoclonal Antibody	CSB-RA007479A1092phHU	EGFR	Human	ELISA, WB
Phospho-EGFR (Y1068) Recombinant Monoclonal Antibody	CSB-RA007479A1068phHU	EGFR	Human	ELISA, WB
EGFR Recombinant Monoclonal Antibody	CSB-RA159341A0HU	EGFR	Human	ELISA, WB, IHC, IF, FC
EGFR Recombinant Monoclonal Antibody	CSB-RA794061A0HU	EGFR	Human	ELISA, WB, IHC
EGFR Recombinant Monoclonal Antibody	CSB-RA159341MA1HU	EGFR	Human	ELISA, IHC, FC
EPCAM Recombinant Monoclonal Antibody	CSB-RA932207A0HU	EPCAM	Human	ELISA, WB

● ELISA試劑盒

產品名稱	貨號	靶點	檢測范圍	靈敏度
Human Carbonic Anhydrase 9(CA9) ELISA Kit	CSB-E13266h	CA9	31.25 pg/mL-2000 pg/mL	7.81 pg/mL
Human T-cell surface glycoprotein CD3 zeta chain (CD247) ELISA kit	CSB-EL004904HU	CD247	0.156 ng/mL-10 ng/mL	0.039 ng/mL
Human Programmed Death Ligand-1(PD-L1/CD274) ELISA Kit	CSB-E13644h	CD274	15.6 pg/mL-1000 pg/mL	3.9 pg/mL
Mouse Programmed cell death 1 ligand 1(CD274) ELISA kit	CSB-EL004911MO	CD274	31.25 pg/mL-2000 pg/mL	7.81 pg/mL
Human Soluble CD276,sCD276/sB7-H3 ELISA Kit	CSB-E14285h	CD276	3.12 ng/mL-200 ng/mL	0.78 ng/mL
Human soluble cluster of differentiation 28,sCD28 ELISA Kit	CSB-E09296h	CD28	0.625 ng/mL-40 ng/mL	0.156 ng/mL
Mouse Tumor necrosis factor receptor superfamily member 5(CD40) ELISA kit	CSB-EL004936MO	CD40	Request Information	Request Information
Human cluster Of differentiation,CD44 ELISA Kit	CSB-E11846h	CD44	78 pg/mL-5000 pg/mL	19.5 pg/mL
Human Leukocyte surface antigen CD47(CD47) ELISA kit	CSB-EL004940HU	CD47	3.12 pg/mL-200 pg/mL	0.78 pg/mL
Mouse Leukocyte surface antigen CD47(CD47) ELISA kit	CSB-EL004940MO	CD47	15.6 pg/mL-1000 pg/mL	3.9 pg/mL
Human carcinoembryonic antigen,CEA ELISA Kit	CSB-E04767h	CEACAM5	5 ng/mL-120 ng/mL	2 ng/mL
Mouse carcinoembryonic antign,CEA ELISA Kit	CSB-E13925m	CEACAM5	62.5 pg/mL-4000 pg/mL	15.6 pg/mL
Human Macrophage Colony-Stimulating Factor Receptor,M-CSFR ELISA Kit	CSB-E10012h	CSF1R	0.156 ng/mL-10 ng/mL	0.039 ng/mL
Rat Macrophage colony-stimulating factor 1 receptor(CSF1R) ELISA kit	CSB-EL006044RA	CSF1R	0.312 ng/mL-20 ng/mL	0.078 ng/mL
Human Granulocyte-Macrophage Colony Stimulating Factor,GM-CSF ELISA Kit	CSB-E04568h	CSF2	15.6 pg/mL-1000 pg/mL	3.9 pg/mL
Mouse Granulocyte-Macrophage Colony Stimulating Factor,GM-CSF ELISA Kit	CSB-E04569m	CSF2	15.6 pg/mL-1000 pg/mL	3.9 pg/mL
Rat Granulocyte-Macrophage Colony Stimulating Factor,GM-CSF ELISA Kit	CSB-E04570r	CSF2	15.6 pg/ml - 1000 pg/ml	3.9 pg/ml
Human cytotoxic T lymphocyte associated antigen 4,CTLA-4 ELISA Kit	CSB-E09171h	CTLA4	125 pg/mL-8000 pg/mL	31.25 pg/mL
Mouse cytotoxic T lymphocyte associated antigen 4,CTLA-4 ELISA Kit	CSB-E13637m	CTLA4	0.312 ng/mL-20 ng/mL	0.078 ng/mL
Human epidermal growth factor receptor,EGFR ELISA Kit	CSB-E12124h	EGFR	0.312 ng/mL-20 ng/mL	0.019 ng/mL

點擊查看華美生物細胞因子檢測ELISA試劑盒

藥物研發解決方案

ADC藥物研發解決方案

mRNA疫苗研究解決方案

CAR-T細胞治療開發解決方案

特色服務項目

專家講堂

【華美講堂第十五期】抗Payload抗體：ADC藥代動力學（PK）的有效分析工具

【華美講堂第十四期】跨越“膜”界：跨膜蛋白助力抗體藥物快速發展

【華美講堂第十三期】抗體內化效率檢測利器助力ADC藥物研發

【華美講堂第十二期】探索抗獨特型抗體

【華美講堂第十期】抗體-藥物偶聯物（ADC）的研發現狀和挑戰

【華美講堂第九期】跨膜蛋白技術平臺在新藥研發中的應用

參考文獻：

1. Cell 186, April 13, 2023

2. Larissa A. Korde, Mark R. Somerfield, Dawn L. Hershman, et al. Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update. DOI: 10.1200/JCO.22.00503 Journal of Clinical Oncology

3. Lajos Pusztai, Carsten Denkert, Joyce O'Shaughnessy, et al. Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. J Clin Oncol 40, 2022 (suppl 16; abstr 503). DOI: 10.1200/JCO.2022.40.16_suppl.503

4. Breast cancer-WHO: https://www.who.int/news-room/fact-sheets/detail/breast-cancer

藥物靶點

腫瘤